# Peptide and GLP-1 dosing chart

Source: https://aminodesk.com/dosing-chart
Publisher: Amino Desk
Updated: 2026-11-18
Clinical review: completed 2026-11-18

Every compound in the library on one page: the approved dose where one exists, and the range people report using. The two columns are not equivalent, and most compounds here have no approved dose at all.

- **Approved dose** comes from an FDA label, or from trial or foreign-label doses where the row says so.
- **Community-reported** is what sellers, clinics and users say they take. It is not a recommendation, and for most compounds no human study has tested it. Tap *Risks* on any row for where the figure comes from and the specific risk attached to it.
- A dose from a prescriber overrides anything on this page. If you are working out syringe units, use the [calculator](https://aminodesk.com/calculator).

Filter the chart

| Compound and main uses | Approved dose | Community-reported (not a recommendation) |
| --- | --- | --- |
| [5-amino-1MQ](https://aminodesk.com/library/5-amino-1mq) Evidence D Fat loss and "metabolic" support; Holding on to muscle while dieting | None | One widely read guide lists 250 to 500 micrograms a day [Risks](https://aminodesk.com/library/5-amino-1mq#community-dosing) |
| [Adamax](https://aminodesk.com/library/adamax) Evidence D Focus and mental drive | None | 50 to 150 micrograms a day as a nasal spray, in short runs of about two weeks [Risks](https://aminodesk.com/library/adamax#community-dosing) |
| [Adipotide](https://aminodesk.com/library/adipotide) Evidence D Fat loss | None | 0.5 to 1 mg under the skin once a day, with 0.5 mg described as a common starting amount [Risks](https://aminodesk.com/library/adipotide#community-dosing) |
| [AHK-Cu (copper tripeptide)](https://aminodesk.com/library/ahk-cu) Evidence D Thinning hair, in scalp serums; Skin firmness | None | No figure we can attribute |
| [AOD-9604](https://aminodesk.com/library/aod-9604) Evidence B Fat loss; Joint pain, usually alongside other injections | None. Trials used 1 to 30 mg by mouth | 250 to 500 micrograms under the skin once a day, most often about 300 micrograms [Risks](https://aminodesk.com/library/aod-9604#community-dosing) |
| [ARA-290 (cibinetide)](https://aminodesk.com/library/ara-290) Evidence B Nerve pain from small-fibre neuropathy; Recovery after nerve injury | None approved | 4 mg under the skin once a day [Risks](https://aminodesk.com/library/ara-290#community-dosing) |
| [BPC-157](https://aminodesk.com/library/bpc-157) Evidence C Tendon, ligament and muscle injuries; Joint pain | None | 250 to 500 micrograms once or twice a day, injected or by mouth [Risks](https://aminodesk.com/library/bpc-157#community-dosing) |
| [BPC-157 + KPV blend](https://aminodesk.com/library/bpc-157-kpv) Evidence D Gut complaints and inflammation | None | No figure we can attribute |
| [Cagrilintide (and CagriSema)](https://aminodesk.com/library/cagrilintide) Evidence B Obesity, combined with semaglutide as CagriSema; Added to tirzepatide or retatrutide for more weight loss | None approved. Trial target: 2.4 mg a week | 0.25 mg once a week at the start, stepped up every four weeks toward 2.4 mg a week [Risks](https://aminodesk.com/library/cagrilintide#community-dosing) |
| [CagriSema (cagrilintide + semaglutide)](https://aminodesk.com/library/cagrisema) Evidence B Obesity and type 2 diabetes; A do-it-yourself version from separate vials | None approved. Trial target: 2.4 mg of each drug a week | Users source cagrilintide and semaglutide separately and aim for the trial target of 2.4 mg of each once a week [Risks](https://aminodesk.com/library/cagrisema#community-dosing) |
| [Cartalax](https://aminodesk.com/library/cartalax) Evidence D Joint and cartilage complaints | None | 2 mg a day, in courses of four to eight weeks [Risks](https://aminodesk.com/library/cartalax#community-dosing) |
| [Cerebrolysin](https://aminodesk.com/library/cerebrolysin) Evidence B Stroke recovery, dementia and brain injury; Sharper thinking in healthy people | None | 5 to 10 mL injected into muscle [Risks](https://aminodesk.com/library/cerebrolysin#community-dosing) |
| [CJC-1295](https://aminodesk.com/library/cjc-1295) Evidence C Raising growth hormone for muscle, fat loss, sleep and recovery | None | One widely read guide lists 2 to 4 mg once a week for the DAC version, and 100 to 300 micrograms a day for the version without DAC [Risks](https://aminodesk.com/library/cjc-1295#community-dosing) |
| [CJC-1295 + ipamorelin + tesamorelin blend](https://aminodesk.com/library/cjc-1295-ipamorelin-tesamorelin) Evidence D Raising growth hormone for fat loss and recovery | None | No figure we can attribute |
| [CJC-1295 + ipamorelin blend](https://aminodesk.com/library/cjc-1295-ipamorelin) Evidence D Raising growth hormone for muscle, fat loss, sleep and recovery | None | 100 to 300 micrograms of each, usually at bedtime [Risks](https://aminodesk.com/library/cjc-1295-ipamorelin#community-dosing) |
| [Cortagen](https://aminodesk.com/library/cortagen) Evidence D Brain and nerve "support" | None | No figure we can attribute |
| [Dihexa](https://aminodesk.com/library/dihexa) Evidence D Memory, focus and "brain growth" | None | 5 to 40 mg a day by mouth, or 8 to 12 mg a day under the tongue [Risks](https://aminodesk.com/library/dihexa#community-dosing) |
| [DSIP (delta sleep-inducing peptide)](https://aminodesk.com/library/dsip) Evidence C Falling asleep and staying asleep | None | 100 to 400 micrograms under the skin in the evening, in runs of two to four weeks [Risks](https://aminodesk.com/library/dsip#community-dosing) |
| [Dulaglutide (Trulicity)](https://aminodesk.com/library/dulaglutide) Evidence A Type 2 diabetes; Lowering cardiovascular risk in adults with type 2 diabetes | 0.75 mg a week, raised in steps up to 4.5 mg | No figure we can attribute |
| [Eloralintide](https://aminodesk.com/library/eloralintide) Evidence B Obesity; Weight loss from research vials | None approved. Trial doses are described on this page | No figure we can attribute |
| [Epitalon](https://aminodesk.com/library/epitalon) Evidence C "Anti-ageing" and telomere claims; Sleep and body clock | None | 5 to 10 mg a day by injection for 10 to 20 days, repeated every four to six months [Risks](https://aminodesk.com/library/epitalon#community-dosing) |
| [Epitalon + MOTS-c blend](https://aminodesk.com/library/epitalon-mots-c) Evidence D "Longevity" and energy | None | No figure we can attribute |
| [FGL (FG loop peptide)](https://aminodesk.com/library/fgl) Evidence C Memory and thinking | None | No figure we can attribute |
| [FOXO4-DRI](https://aminodesk.com/library/foxo4-dri) Evidence D Clearing aged "senescent" cells for anti-ageing | None | 1 to 5 mg every three days, for one to two weeks [Risks](https://aminodesk.com/library/foxo4-dri#community-dosing) |
| [GHK-Cu + BPC-157 blend](https://aminodesk.com/library/ghk-cu-bpc-157) Evidence D Skin and injury recovery | None | No figure we can attribute |
| [GHK-Cu + KPV blend](https://aminodesk.com/library/ghk-cu-kpv) Evidence D Skin and inflammation | None | No figure we can attribute |
| [GHK-Cu and the Glow stack](https://aminodesk.com/library/ghk-cu) Evidence C Skin ageing: firmness, texture, fine lines; Scars and wound healing | None | Injected: 1 to 2 mg a day, or 1 to 2.5 mg two or three times a week [Risks](https://aminodesk.com/library/ghk-cu#community-dosing) |
| [GHRP-2 and GHRP-6](https://aminodesk.com/library/ghrp-2-ghrp-6) Evidence C Raising growth hormone for muscle and recovery; Appetite and weight gain, mainly GHRP-6 | None | 100 to 300 micrograms per injection under the skin, up to three times a day [Risks](https://aminodesk.com/library/ghrp-2-ghrp-6#community-dosing) |
| [GLOW blend (GHK-Cu + BPC-157 + TB-500)](https://aminodesk.com/library/glow-blend) Evidence D Skin quality; Injury recovery | None | 1.4 to 4.2 mg of the blend per injection, which carries 1 to 3 mg of GHK-Cu and 200 to 600 micrograms each of BPC-157 and TB-500 [Risks](https://aminodesk.com/library/glow-blend#community-dosing) |
| [Glutathione (injectable)](https://aminodesk.com/library/glutathione) Evidence C Skin lightening; "Detox" and antioxidant support | None | 200 to 600 mg by injection, three times a week [Risks](https://aminodesk.com/library/glutathione#community-dosing) |
| [Gonadorelin](https://aminodesk.com/library/gonadorelin) Evidence C Keeping testicle function and fertility while on testosterone; Restoring fertility in a rare hormone deficiency, given by pump | None for use alongside testosterone | No figure we can attribute |
| [Growth hormone (HGH)](https://aminodesk.com/library/growth-hormone) Evidence A Growth hormone deficiency in children and adults, and several named growth and wasting conditions; "Anti-ageing" | Set individually against blood tests | 0.5 to 4 IU a day by injection [Risks](https://aminodesk.com/library/growth-hormone#community-dosing) |
| [HCG](https://aminodesk.com/library/hcg) Evidence A Triggering ovulation in fertility treatment; Low testosterone caused by a pituitary signalling problem in men | Set by the treating specialist for each approved use | 150 to 500 IU every other day, alongside testosterone [Risks](https://aminodesk.com/library/hcg#community-dosing) |
| [Hexarelin](https://aminodesk.com/library/hexarelin) Evidence C Raising growth hormone for muscle and recovery | None | 100 to 200 micrograms under the skin, two or three times a day [Risks](https://aminodesk.com/library/hexarelin#community-dosing) |
| [Humanin](https://aminodesk.com/library/humanin) Evidence D "Longevity" and brain protection | None | 1 to 3 mg of native humanin under the skin two or three times a week, or 100 to 500 micrograms of the stronger HNG version on the same schedule [Risks](https://aminodesk.com/library/humanin#community-dosing) |
| [IGF-1 LR3](https://aminodesk.com/library/igf-1-lr3) Evidence D Muscle growth | None | 20 to 80 micrograms a day by injection [Risks](https://aminodesk.com/library/igf-1-lr3#community-dosing) |
| [Ipamorelin](https://aminodesk.com/library/ipamorelin) Evidence C Raising growth hormone for sleep, recovery and body composition | None | 100 to 300 micrograms under the skin, usually at bedtime [Risks](https://aminodesk.com/library/ipamorelin#community-dosing) |
| [Khavinson short peptides: Bronchogen, Cardiogen and seven more](https://aminodesk.com/library/khavinson-bioregulators) Evidence D "Support" for a named organ: lungs, heart, liver, prostate and so on | None | No figure we can attribute |
| [Kisspeptin](https://aminodesk.com/library/kisspeptin) Evidence B Triggering egg maturation in IVF; Low sexual desire | None | 100 to 500 micrograms of kisspeptin-10, three times a week [Risks](https://aminodesk.com/library/kisspeptin#community-dosing) |
| [KLOW blend (GHK-Cu + BPC-157 + TB-500 + KPV)](https://aminodesk.com/library/klow-blend) Evidence D Skin quality; Injury recovery and inflammation | None | 1.6 to 4.8 mg of the blend per injection, which carries 1 to 3 mg of GHK-Cu and 200 to 600 micrograms each of BPC-157, TB-500 and KPV [Risks](https://aminodesk.com/library/klow-blend#community-dosing) |
| [KPV](https://aminodesk.com/library/kpv) Evidence D Gut inflammation, including inflammatory bowel disease; Inflamed skin, applied as a cream | None | 200 to 500 micrograms a day [Risks](https://aminodesk.com/library/kpv#community-dosing) |
| [L-carnitine (injectable)](https://aminodesk.com/library/l-carnitine) Evidence B Carnitine deficiency, including in people on dialysis; Weight-loss injections | 10 to 20 mg per kilogram into a vein after dialysis. None for weight loss | 200 to 500 mg a day by injection [Risks](https://aminodesk.com/library/l-carnitine#community-dosing) |
| [Larazotide](https://aminodesk.com/library/larazotide) Evidence B Celiac disease; "Leaky gut" | None | No figure we can attribute |
| [Lipo-C and Lipo-C + B12 (MIC lipotropic injections)](https://aminodesk.com/library/lipo-c) Evidence D Weight loss, sold as a "skinny shot"; Energy | None | No figure we can attribute |
| [Liraglutide (Saxenda, Victoza)](https://aminodesk.com/library/liraglutide) Evidence A Long-term weight management; Type 2 diabetes, including lowering cardiovascular risk | Saxenda: 0.6 mg a day, raised weekly to 3 mg | No figure we can attribute |
| [LL-37 (cathelicidin)](https://aminodesk.com/library/ll-37) Evidence C Hard-to-heal leg ulcers, applied to the wound; Infections, "biofilms" and immune support, by injection | None | 100 to 200 micrograms under the skin once a day, often five days on and two off [Risks](https://aminodesk.com/library/ll-37#community-dosing) |
| [Mazdutide](https://aminodesk.com/library/mazdutide) Evidence B Weight management and type 2 diabetes; Weight loss from research vials | None in the US. Trials: 3 to 9 mg a week | 3 to 9 mg once a week [Risks](https://aminodesk.com/library/mazdutide#community-dosing) |
| [Melanotan I (afamelanotide, Scenesse)](https://aminodesk.com/library/melanotan-i) Evidence A Erythropoietic protoporphyria, a rare light-sensitivity disorder; Tanning, using injected powder sold as Melanotan I | 16 mg implant every two months, placed by a clinician | 500 to 1,000 micrograms by injection, twice a week [Risks](https://aminodesk.com/library/melanotan-i#community-dosing) |
| [Melanotan II](https://aminodesk.com/library/melanotan-ii) Evidence C Tanning; Libido and erections | None | 250 to 500 micrograms under the skin once a day for one to four weeks, then about 500 micrograms once or twice a week [Risks](https://aminodesk.com/library/melanotan-ii#community-dosing) |
| [Methylene blue](https://aminodesk.com/library/methylene-blue) Evidence A Methemoglobinemia, a blood disorder; Memory, focus and energy | 1 mg per kilogram into a vein, in hospital. None for other uses | Anywhere from 0.5 to 5 mg a few times a week to 5 to 20 mg a day, by mouth [Risks](https://aminodesk.com/library/methylene-blue#community-dosing) |
| [MK-677 (ibutamoren)](https://aminodesk.com/library/mk-677) Evidence B Muscle gain; Sleep and appetite | None approved. Trials: 25 mg a day | 10 to 25 mg a day by mouth [Risks](https://aminodesk.com/library/mk-677#community-dosing) |
| [MOTS-c](https://aminodesk.com/library/mots-c) Evidence D Fat loss and "metabolic" health; Exercise performance | None | 5 to 10 mg under the skin two or three times a week [Risks](https://aminodesk.com/library/mots-c#community-dosing) |
| [N-acetyl Selank amidate](https://aminodesk.com/library/n-acetyl-selank) Evidence D Anxiety and stress | None | No figure we can attribute |
| [N-acetyl Semax amidate](https://aminodesk.com/library/n-acetyl-semax) Evidence D Focus and mental energy | None | No figure we can attribute |
| [NAD+](https://aminodesk.com/library/nad) Evidence D Energy and fatigue, including after illness; "Anti-ageing" | None | Into muscle: 50 to 200 mg, two or three times a week. Under the skin: 50 to 100 mg. By drip: 500 to 1,000 mg over two to four hours [Risks](https://aminodesk.com/library/nad#community-dosing) |
| [Oxytocin](https://aminodesk.com/library/oxytocin) Evidence B Starting or strengthening labour; Social difficulties in autism, as a nasal spray | Hospital drip only. None for the nasal spray | 10 to 20 IU as a nasal spray, as needed [Risks](https://aminodesk.com/library/oxytocin#community-dosing) |
| [P21 (P021)](https://aminodesk.com/library/p21) Evidence D Memory and learning | None | 100 to 500 micrograms a day [Risks](https://aminodesk.com/library/p21#community-dosing) |
| [PE-22-28](https://aminodesk.com/library/pe-22-28) Evidence D Low mood | None | 200 to 400 micrograms a day as a nasal spray, or 100 to 200 micrograms a day by injection [Risks](https://aminodesk.com/library/pe-22-28#community-dosing) |
| [PEG-MGF (mechano growth factor)](https://aminodesk.com/library/peg-mgf) Evidence D Muscle growth and repair | None | 200 to 400 micrograms per injection, two or three times a week [Risks](https://aminodesk.com/library/peg-mgf#community-dosing) |
| [Pentosan polysulfate (Elmiron)](https://aminodesk.com/library/pentosan-polysulfate) Evidence A Bladder pain from interstitial cystitis; Osteoarthritis, as injections | See the label dose below | No figure we can attribute |
| [Pinealon](https://aminodesk.com/library/pinealon) Evidence D Memory, thinking and sleep | None | 1 to 2 mg a day by injection for 10 to 20 days, or capsules of about 20 mg a day by mouth [Risks](https://aminodesk.com/library/pinealon#community-dosing) |
| [PNC-27](https://aminodesk.com/library/pnc-27) Evidence D Sold online as a cancer treatment | None | Not published |
| [Progesterone](https://aminodesk.com/library/progesterone) Evidence A Protecting the womb lining in women taking estrogen after menopause; Absent periods (secondary amenorrhea) | 200 mg at bedtime for 12 days of each cycle, with estrogen | No figure we can attribute |
| [PT-141 (bremelanotide, Vyleesi)](https://aminodesk.com/library/pt-141) Evidence A Low sexual desire in premenopausal women; Erectile problems and libido in men | 1.75 mg as needed, at most one dose in 24 hours and eight a month | 1.75 mg under the skin as needed, the same as the label dose [Risks](https://aminodesk.com/library/pt-141#community-dosing) |
| [PT-141 + oxytocin blend](https://aminodesk.com/library/pt-141-oxytocin) Evidence D Libido and arousal | None | No figure we can attribute |
| [Rapamycin (sirolimus)](https://aminodesk.com/library/rapamycin) Evidence B Preventing kidney transplant rejection; Lymphangioleiomyomatosis, a rare lung disease | Label doses are for transplant and lung disease. Longevity trial: 5 or 10 mg once a week | No figure we can attribute |
| [Retatrutide](https://aminodesk.com/library/retatrutide) Evidence B Obesity and weight-related conditions; Type 2 diabetes | None approved. Trials: 2 mg a week, stepped up to 9 or 12 mg | 0.5 to 12 mg once a week [Risks](https://aminodesk.com/library/retatrutide#community-dosing) |
| [Retatrutide + cagrilintide blend](https://aminodesk.com/library/retatrutide-cagrilintide) Evidence D Maximum weight loss | None | Users start cagrilintide at 0.25 mg a week once retatrutide is established, and step both up over months toward 12 mg of retatrutide and 2.4 mg of cagrilintide a week [Risks](https://aminodesk.com/library/retatrutide-cagrilintide#community-dosing) |
| [Selank](https://aminodesk.com/library/selank) Evidence C Anxiety; Stress and focus | None | 250 to 500 micrograms a day as a nasal spray [Risks](https://aminodesk.com/library/selank#community-dosing) |
| [Semaglutide (Wegovy, Ozempic)](https://aminodesk.com/library/semaglutide) Evidence A Long-term weight management; Type 2 diabetes | 0.25 mg a week, raised in steps to 2.4 mg (injection) | Microdosing: 0.1 to 0.25 mg once a week [Risks](https://aminodesk.com/library/semaglutide#off-label-dosing) |
| [Semax](https://aminodesk.com/library/semax) Evidence C Stroke recovery and thinking problems; Focus and mental energy in healthy people | None in the US. Russian clinical practice is described below | 200 to 600 micrograms as a nasal spray, once or twice a day, in runs of 10 to 14 days [Risks](https://aminodesk.com/library/semax#community-dosing) |
| [Semax + Selank blend](https://aminodesk.com/library/semax-selank) Evidence D Focus without anxiety | None | No figure we can attribute |
| [Sermorelin](https://aminodesk.com/library/sermorelin) Evidence B Growth hormone deficiency in children; Sleep, recovery and body composition in adults | None | 200 to 500 micrograms under the skin at night [Risks](https://aminodesk.com/library/sermorelin#community-dosing) |
| [SLU-PP-332](https://aminodesk.com/library/slu-pp-332) Evidence D Endurance and fat loss, sold as "exercise in a pill" | None | There is no agreed figure [Risks](https://aminodesk.com/library/slu-pp-332#community-dosing) |
| [SNAP-8 (acetyl octapeptide-3)](https://aminodesk.com/library/snap-8) Evidence C Expression lines, in creams and serums | None | No figure we can attribute |
| [SS-31 (elamipretide, Forzinity)](https://aminodesk.com/library/ss-31) Evidence B Barth syndrome; Fatigue, "mitochondrial support" and exercise performance | 40 mg a day, for people 30 kg or heavier | 1 to 5 mg under the skin once a day is the most common report, within a wider range of 1 to 10 mg [Risks](https://aminodesk.com/library/ss-31#community-dosing) |
| [Survodutide](https://aminodesk.com/library/survodutide) Evidence B Obesity; MASH, a serious fatty liver disease | None approved. Trials: 3.6 or 6 mg a week after slow steps | 0.3 to 6 mg once a week, starting low [Risks](https://aminodesk.com/library/survodutide#community-dosing) |
| [TB-500](https://aminodesk.com/library/tb-500) Evidence D Muscle, tendon and ligament injuries; Recovery after surgery | None | 2 to 4 mg twice a week [Risks](https://aminodesk.com/library/tb-500#community-dosing) |
| [Tesamorelin (Egrifta)](https://aminodesk.com/library/tesamorelin) Evidence A Excess abdominal fat in adults with HIV and lipodystrophy; Fatty liver disease | Once a day; the milligram amount depends on the formulation | 1 to 2 mg under the skin once a day [Risks](https://aminodesk.com/library/tesamorelin#off-label-dosing) |
| [Tesamorelin + ipamorelin blend](https://aminodesk.com/library/tesamorelin-ipamorelin) Evidence D Belly fat and recovery | None | No figure we can attribute |
| [Tesofensine](https://aminodesk.com/library/tesofensine) Evidence B Weight loss | None approved. Trial doses are described on this page | No figure we can attribute |
| [Testosterone (cypionate, enanthate)](https://aminodesk.com/library/testosterone) Evidence A Low testosterone with an associated medical condition; Age-related low testosterone | Cypionate: 50 to 400 mg every two to four weeks | No figure we can attribute |
| [Thymalin](https://aminodesk.com/library/thymalin) Evidence C Immune problems; "Longevity" | None | 5 to 10 mg a day into muscle for 5 to 10 days, repeated as occasional courses [Risks](https://aminodesk.com/library/thymalin#community-dosing) |
| [Thymogen (Glu-Trp)](https://aminodesk.com/library/thymogen) Evidence C Immune support | None | No figure we can attribute |
| [Thymosin alpha-1](https://aminodesk.com/library/thymosin-alpha-1) Evidence B Hepatitis B, and as an immune booster with vaccines; General immune support, chronic infections and fatigue | None in the US. Abroad: 1.6 mg twice a week | 1.6 mg under the skin twice a week [Risks](https://aminodesk.com/library/thymosin-alpha-1#community-dosing) |
| [Thymulin](https://aminodesk.com/library/thymulin) Evidence D Immune support | None | 5 to 10 mg a day for one to two weeks [Risks](https://aminodesk.com/library/thymulin#community-dosing) |
| [Tirzepatide (Zepbound, Mounjaro)](https://aminodesk.com/library/tirzepatide) Evidence A Long-term weight management; Type 2 diabetes | 2.5 mg a week to start, then 5 to 15 mg | Microdosing: 0.5 to 2 mg once a week [Risks](https://aminodesk.com/library/tirzepatide#off-label-dosing) |
| [Tirzepatide + BPC-157 blend](https://aminodesk.com/library/tirzepatide-bpc-157) Evidence D Weight loss with fewer stomach side effects | None | No figure we can attribute |
| [Vesugen](https://aminodesk.com/library/vesugen) Evidence D Blood vessel "support" | None | No figure we can attribute |
| [Vilon (Lys-Glu)](https://aminodesk.com/library/vilon) Evidence D Immune support and "anti-ageing" | None | 100 to 500 micrograms a day under the skin, or one to two capsules a day for 10 to 30 days [Risks](https://aminodesk.com/library/vilon#community-dosing) |
| [VIP (vasoactive intestinal peptide, aviptadil)](https://aminodesk.com/library/vip) Evidence C Chronic inflammatory illness blamed on mould exposure, as a nasal spray; Brain fog and heat intolerance | None | 25 to 200 micrograms a day as a nasal spray [Risks](https://aminodesk.com/library/vip#community-dosing) |
| [Vitamin B12 injections (cyanocobalamin)](https://aminodesk.com/library/vitamin-b12) Evidence A B12 deficiency, including pernicious anemia; Energy and weight-loss shots in people who are not deficient | See the label dose below | No figure we can attribute |
| [Wolverine blend (BPC-157 + TB-500)](https://aminodesk.com/library/wolverine-blend) Evidence D Tendon, ligament and muscle injuries; Recovery after surgery or hard training | None | 250 to 500 micrograms of BPC-157 a day, with 1 to 2.5 mg of TB-500 two or three times a week [Risks](https://aminodesk.com/library/wolverine-blend#community-dosing) |

This chart is a summary of the library pages as of November 18, 2026. Each compound's own page is the full and current version, with sources. Evidence grades run from A (strong human evidence) to D (little or none) and describe evidence, not safety.

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
